ClinicalTrials.Veeva

Menu

A Phase II Optimization Study of BMS068645 and Sestamibi Planar Imaging

Forest Laboratories logo

Forest Laboratories

Status and phase

Terminated
Phase 2

Conditions

Ischemic Heart Disease
Cardiovascular Disease

Treatments

Drug: apadenoson

Study type

Interventional

Funder types

Industry

Identifiers

NCT00162071
BMS068645-203

Details and patient eligibility

About

The primary purpose of this study is to determine the optimal time for myocardial perfusion imaging with Technetium Tc99m Sestamibi following the administration of BMS068645. The safety of BMS068645 will also be studied.

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • 18 years of age or older
  • Have known or suspected heart disease
  • Have undergone a clinically indicated SPECT MPI study with adenosine in the last 24 hours to 14 days.
  • Weigh between 88 and 250 lbs.

Exclusion criteria

  • Allergic reaction to Technetium Tc99m Sestamibi or any of its components
  • History of asthma or lung disease
  • Ingestion of caffeinated substances within 12 hours prior to the study

Trial design

Primary purpose

Diagnostic

Allocation

Non-Randomized

Interventional model

Single Group Assignment

Masking

None (Open label)

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems